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Genomic variations in patients 
with myelodysplastic syndrome 
and karyotypes without numerical 
or structural changes
Cristiano Luiz Ribeiro 1,5*, Irene P. Pinto1,5, Samara S. S. Pereira1, Lysa B. Minasi1, 
Fernanda de S. M. Kluthcouski3, Adriano de M. Arantes4, Aparecido D. da Cruz1,2,5, 
Marcio A. A. de Almeida6, Tom E. Howard6 & Cláudio C. da Silva1,2,5
Myelodysplastic syndrome (MDS) is an onco-hematologic disease with distinct levels of peripheral 
blood cytopenias, dysplasias in cell differentiation and various forms of chromosomal and 
cytogenomic alterations. In this study, the Chromosomal Microarray Analysis (CMA) was performed 
in patients with primary MDS without numerical and/or structural chromosomal alterations in 
karyotypes. A total of 17 patients was evaluated by GTG banding and eight patients showed no 
numerical and/or structural alterations. Then, the CMA was carried out and identified gains and losses 
CNVs and long continuous stretches of homozygosity (LCSHs). They were mapped on chromosomes 1, 
2, 3, 4, 5, 6, 7, 9, 10, 12, 14, 16, 17, 18, 19, 20, 21, X, and Y. Ninety-one genes that have already been 
implicated in molecular pathways important for cell viability were selected and in-silico expression 
analyses demonstrated 28 genes differentially expressed in mesenchymal stromal cells of patients. 
Alterations in these genes may be related to the inactivation of suppressor genes or the activation 
of oncogenes contributing to the evolution and malignization of MDS. CMA provided additional 
information in patients without visible changes in the karyotype and our findings could contribute 
with additional information to improve the prognostic and personalized stratification for patients.
Onco-hematologic diseases constitute a group of neoplasms with different degrees of bone marrow insufficiency, 
characterized by the expansion of cells with ineffective hematopoietic  functions1,2. Myelodysplastic syndrome 
(MDS) comprises a heterogeneous subgroup of neoplasms of bone marrow clones, which present different levels 
of cytopenia in the peripheral blood, abnormal differentiation of the myeloid lineage, and dysplastic myeloid 
 changes1,3. Chromosomal and/or genomic instability inherent in MDS is associated with an increased risk of 
unfavorable clinical evolution and the development of acute myeloid leukemia (AML), which can occur in 20 
to 40% of primary MDS  cases1,4.
The estimated population incidence rate of MDS is four patients per 100.000 individuals per year in the gen-
eral population. With advancing age, the incidence of MDS significantly increases. For the age group ≥ 80 years, 
the incidence of MDS increases 12.5-fold5. The average age of onset is 60  years6 and only 10% of patients are 
under 50 years  old5,7. Chromosomal changes are observed in approximately 50% of primary MDS and 80 to 
90% of secondary  neoplasms8–11. Karyotype data provides important variables for the diagnosis and prognosis 
of primary MDS, according to the consensus of the International Working Group for the Prognosis of MDS 
(IWG-PM) of the Myelodysplastic Syndrome Foundation, Inc. The MDS-Foundation proposed the International 
Prognostic Scoring System Revised (IPSS-R), in which cytogenetic abnormalities are used to predict the overall 
survival and risk of primary MDS  transformation6.
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The Chromosomal Microarray Analysis (CMA) based on single-nucleotide polymorphism (SNP) is a robust 
methodology for genomic prospection and, therefore, is useful for investigating cytogenomic rearrangements 
in  MDS3,12. The use of CMA could improve MDS diagnosis, refine risk stratification, and provide additional 
genomic information that can be applied in patient handling and  management13. The CMA allows for the accurate 
detection of copy-number variation (CNV) and long continuous stretches of homozygosity (LCSH) acquired 
in cell-clone neoplasms of MDS patients. This analysis is particularly important in cases where the karyotype 
was unable to identify chromosomal rearrangements or could not be performed on biological  samples2,14–18.
Previous studies have implicated LCSHs in the genomic instability observed in patients with  MDS19,20. LCSHs 
occur in about 50% of MDS patients with karyotypes without numerical and/or structural alterations. There-
fore, genomic variations like LCSH play an important role in tumorigenesis and can alter gene  expression21,22. 
CNVs and LCSHs demonstrate prognostic significance in MDS and  AML21. Previous studies have shown that 
74% of the patients evaluated by molecular or cytogenomic techniques present at least one oncogenic copy or 
pathogenic CNV related to the etiology and development of MDS. Changes in molecular pathways involving 
epigenetic regulation, chromatin modification, transcriptional regulation, signal transduction, apoptosis, RNA 
splicing, and cell cycle control in mesenchymal stromal cells in the medullary microenvironment may alter 
hematopoiesis in  MDS10,23–26.
In the context previously described, the overall objective of the present study was to identify CNVs and LCSHs 
by applying the CMA using high-density SNP arrays in patients with primary MDS whose karyotypes presented 
without numerical and/or structural chromosomal alterations.
Materials and methods
Patients and biological materials. This study was conducted at the Replicon Research Center of the 
School of Agricultural and Biological Sciences of the Pontifical Catholic University of Goiás and in the Human 
Cytogenetics and Molecular Genetics Laboratory of the Secretary of Goias State for Public Health. The devel-
opment of this research relied on collaboration with the South Texas Diabetes and Obesity Institute (STDOI), 
Department of Human Genetics, School of Medicine from the University of Texas Rio Grande Valley in the 
United States of America. For each of the 17 patients with MDS, the attending physician collected a total of 4 mL 
of bone marrow tissue. All methods were carried out in accordance with ethical and technical relevant guidelines 
and regulations, following both national and international consensuses. This study was approved by Human 
Research Ethics Committee of the Federal University of Goiás Clinics Hospital (HREC-FUG/HC), under pro-
tocol no. 1.621.064/2016. All research procedure was done in accordance with the Declaration Helsinki. All 
patients signed an informed consent document approved by the Human Research Ethics Committee.
Cytogenetic analysis. Karyotypes from metaphase with a 450-band resolution were obtained through 
cell culture in bone marrow tissue samples from patients with primary MDS. The chromosomes were banded 
by the GTG method (following standard procedures), modified, and optimized in accordance with previ-
ous  protocols27. Short-term cultures (48 h) were established by incubating 1.0 mL of cell suspension in 5 mL 
RPMI1640 (Gibco Life Science, USA) supplemented with 1 mL of fetal bovine serum (Gibco Life Science, USA) 
and 100 μL L-glutamine (Gibco Life Science, USA) at 37 °C and in 5%  CO2. To achieve metaphase, mitotic divi-
sions were interrupted by adding 100 μL of colchicine solution (10 μg/mL) in water (Gibco Life Science, USA) to 
the culture system for 30 min prior to harvesting the cell suspension. Subsequently, the cells were incubated in 
a hypotonic solution of KCl (0.075 M) (Merck KGaA, Germany) for 30 min at 37 °C and in 5%  CO2. Following 
hypotonization, the cells were fixed in methanol solution/glacial acetic acid (3:1), that was added by drip. The 
cells were mixed, centrifuged, and resuspended in fresh fixative solution. The fixation step was repeated three 
to four times. The fixed cells were dripped onto microscopy slides, subjected to GTG chromosome banding 
with the enzyme Trypsin (Invitrogen Life Technologies, USA), and stained in 4% Giemsa solution (Gibco Life 
Science, USA). Trypsin enzyme was diluted in phosphate-buffered saline (Invitrogen Life Technologies, USA). 
Twenty metaphases were analyzed per sample. The metaphase images were captured with the aid of an Axio-
Imager 2 microscope (Carl Zeiss, Germany) connected to the blade-sweeping platform Metafer4 (MetaSystems 
Corporation, Germany). Chromosomal analyses were performed by the software IKAROS (Version 5.0, Meta-
Systems Corporation, Germany).
SNP array analysis. The platform GeneChip CytoScan HD array (Thermo Fisher Scientific, USA) was used 
for the identification of CNVs and LCSHs in the genome of 8/17 patients with primary MDS, who presented 
karyotypes without numerical or structural alterations. The genomic DNA of bone marrow tissue was extracted 
using the DNA GenomicPrep Mini Kit (GE Healthcare, USA) following the manufacturer’s instructions. A total 
of 250 ng of DNA from each sample was digested with the restriction enzyme NspI, following the manufacturer’s 
recommendations (Thermo Fisher Scientific, USA). Once digested, the samples were connected to the adapters, 
and then a universal primer was used to amplify the fragments using restriction fragment length polymorphism 
(RFLP) through polymerase chain reaction (PCR). PCR conditions were optimized to amplify fragments of sizes 
ranging from 150 to 2000 bp in length. The fragments were confirmed on 2% agarose gel in 1X TBE, subjected to 
a constant electric field of 10 V/cm for 1 h, and stained in an aqueous solution of ethidium bromide (5 mg/mL). 
The gel image was captured by the GelDoc XR + Imaging System (Bio-Rad Laboratories, USA).
The amplified products were purified with magnetic beads and quantified on the spectrophotometer NanoVue 
Plus (GE Healthcare, USA). Next, the amplified products were fragmented into 50- to 200-pb segments, purified, 
confirmed on a 4% agarose gel in TBE 1X, and separated in a constant electric field of 10 V/cm/h. The bands 
were revealed in an aqueous solution of ethidium bromide (5 mg/mL). The gel image was captured by the video 
documentation system GelDoc XR + Imaging System (Bio-Rad Laboratories, USA). DNA fragments were tagged 
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with a terminal deoxynucleotidyl transferase and applied to the GeneChip CytoScan HD, followed by hybridiza-
tion for 16–18 h at 50 ºC and 60 rpm in the GeneChip Hybridization Oven 645 (Thermo Fisher Scientific, USA). 
Subsequently, the chips were washed and stained in GeneChip Fluidic Station 450 (Thermo Fisher Scientific, 
USA) and scanned by a GeneChip Scanner 3000 7G (Thermo Fisher Scientific, USA) controlled by the Thermo 
Fisher Scientific GeneChip Command Console (AGCC, Version 3.2.2). The array was designed for cytogenomic 
diagnosis, with approximately a 2.7-million-marker copy number range, covering the entire human genome, 
including 743,304 SNP markers and > 1.9 million non-polymorphic markers. The CEL archives obtained by 
scanning each patient were compared with two databases: DGV (Database of Genomic Variants—http://proje 
cts.tcag.ca/varia tion) and CytoScanHD Array Database (provided by software ChAS). CNVs were also compared 
with the genetic diseases database DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans 
using Ensembl Resources: https ://decip her.sange r.ac.uk/appli catio n/). Additionally, 100% of the constitutional 
genes were covered by The International Standards for Cytogenomic Arrays Consortium (ISCA: https ://www.
iscac onsor tium.org), including about 12,000 genes from OMIM and more than 36,000 genes from the RefSeq 
(Reference Sequence Database/NCBI).
In the ChAS, analysis parameters were fixed at 50 markers and a size of 100 kpb to detect gains and at 25 
markers and a size of 100 kpb to detect losses. The filter was fixed to ≥ 3 Mb to detect the LCSHs. In the study, 
the parameters for CNV analysis followed both standard criteria based on manufacture’s recommendations and 
on the LCSHs analysis previously  reported28,29. All analyzed chips met the quality control metrics, being MAPD 
and SNP-QC defined at ≤ 0.25 and ≥ 15, respectively. CNVs, LCSHs, and genes were identified, selected, and 
separated based on their association with molecular factors of MDS. The databases Online Mendelian Inheritance 
in Man (OMIM) and RefSeq were accessed by software R to support data mining, analysis, and interpretation 
of the cytogenomic information obtained by CMA.
Expression analysis through public databases. Expression analysis was performed on public data-
bases of patients with primary MDS. An NCBI GEO dataset file (https ://www.ncbi.nlm.nih.gov/geo/) was down-
loaded. The study (accession number GSE61853) was based on the analysis of gene expression in mesenchymal 
tissues of bone marrow stromal cells of patients with MDS and normal controls. The transcriptome was inves-
tigated with the aid of the platform Thermo Fisher Scientific Human Gene 1.0 ST Array (USA). Based on the 
global expression profile of bone marrow mesenchymal stem cells (BM MSCs), the top 250 genes were ranked 
based on P-value in the study GSE61853 where smallest P-value were the most significant. Afterwards, we com-
pared the genes selected in the CNVs and LCSHs regions with the top 250 genes from the database. The logFC 
values were used to define which genes were considered to positively or negatively regulated in the individuals 
with MDS involved in this study.
Results
The average age of the 17 patients was 56 (26–79) years. The small sample group is a result of the reduced inci-
dence of primary MDS in the population. Of the 17 cases, in 6/17, the results of karyotype with banding GTG 
demonstrated numerical or structural changes, being + 8, + 15, + 17, + 21, − X, t(4;11)(q21;q23) add(1)(q?), and 
polyploidy clones; in 3/17, the karyotype was not informative, given that there was no clonal expansion, so these 
cases were removed from subsequent analyses. In 8/17 patients, the karyotype showed no numerical and/or 
structural chromosomal changes, and their results were previously reported and were not included in the current 
 analysis30. With assistance from CMA, 41 genomic variants were identified in 7/8 patients with no visible changes 
in karyotype, including 11/41 variations in the number of copies per gain, 2/41 regions with genomic loss, and 
28/41 long continuous extensions of homozygosis, mapped on chromosomes 1, 2, 3, 4, 5, 6, 7, 9, 10, 12, 14, 16, 17, 
18, 19, 20, 21, X, and Y (Figs. 1 and 2). Ninety-one genes that have already been implicated in relevant molecular 
pathways for cell viability were selected, including 9/91 gains and 4/91 losses, and 78/91 in regions with LCSHs.
The cytogenetic risk of patients with karyotypes without numerical or structural alterations was rated as 
good, based on the International Prognostic Scoring System—Revised, while the risk of prognostic transforma-
tion of MDS ranged from very low to low. Only one patient died, while the others remained stable at the end of 
the study. Table 1 summarizes the results identified by the CMA and the risk estimates, according to IPSS-R, in 
addition to the clinical outcomes of these eight primary MDS patients.
The size of the genomic changes varied from 0.1 to 23.4 Mb. The LCSHs were larger when compared with 
the CNVs, ranging from 3.9 to 23.4 Mb. A CNV of loss identified in the cytoband 20q11.21 with 17.1 Mb was 
the largest genomic variant. The biggest CNV of gain was identified in the cytoband 7q36.3 with 0.52 Mb, while 
the lowest genomic gain was in cytoband 3q12.2 with 0.1 Mb.
Among the selected genes, 28/91 are differentially expressed by up-regulation or down-regulation in the 
mesenchymal stromal cells of bone marrow tissue from patients with MDS and karyotypes without numerical or 
structural changes. The value of logFC was used to define which of the 91 selected genes were regulated positively 
or negatively in the MDS patients included in this study. Table 2 shows the biological functions and expression 
patterns of the 28 genes at diagnosis, in addition to the logFC value.
Some recurrent genomic variations have been identified in patients in the present sample group. The 
LCSHs in cytoband 19q13.32 with sizes of 13.64 Mb and 5.48 Mb were identified in patients ONCO003 and 
ONCO005, respectively. In this region, the genes ERCC2, SIX5, SYMPK, STRN4, BBC3, BAX, GYS1, CD37, 
FLT3LG, BCL2L12, and IL4I1, which were common among these patients, were selected. That said, the genes 
SIX5, SYMPK, and FLT3LG were differentially expressed by up-regulation or down-regulation. The LCSHs 
in cytoband 10q26.12 with 3.9 Mb and 10.76 Mb were identified in the patients ONCO003 and ONCO012, 
respectively, and the gene C10orf88 was identified to be differentially expressed by down-regulation. CNVs of 
genomic gain involving cytoband 17p11.2 with different sizes were also identified. In patient ONCO002 with 
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0.29 Mb, the up-regulated oncogene MAP2K3 was selected, and in patient ONCO014 with 0.13 Mb and 0.15 Mb, 
the SPECC1 gene was selected.
Discussion
In the present study, patient karyotypes without numerical and/or structural alterations were classified according 
to cytogenetic risk as good, whereas risk prediction for primary MDS ranged from very low to low. These results 
confirmed that cytogenetic risk is an important informative variable for inferring prognosis because, according to 
the clinical outcomes, only one patient died, while the others remained stable at the end of the study. The CMA 
analysis of patients with primary MDS and no karyotype changes visible under the microscope also provided 
useful information for better understanding of the etiological aspects of this hematological  disease3,8,10,11.
CNVs and LCSHs that are potentially associated with the etiology of MDS were identified in 87.5% (7/8) of 
the patients included in this study, of which 91 genes were selected that had already been implicated in molecular 
pathways important for cell metabolism and viability. According to the Cancer Genomics Consortium (CGC), 
CMA shows efficiency in detecting genomic variations in primary MDS in 10 to 80% of patient karyotypes with-
out numerical or structural chromosomal  changes13. Despite recent advances in diagnostic tools, MDS continues 
Figure 1.  Ideograms of chromosomes following Denver’s group nomenclature summarizing the mapping of 
13 unusual and clinically significant CNVs, identified by CMA in 7/8 MDS patients with karyotypes without 
numerical or structural chromosomal changes. Legend: Blue lines indicate CNVs with genomic gains, while red 
lines indicate CNVs of genomic loss. A dotted green line was added to indicate the alignment of chromosomes 
by centromeres.
Figure 2.  Ideogram of chromosomes following Denver’s group nomenclature summarizing the mapping of 28 
unusual and clinically significant LCSHs, indicated by purple bars, identified by CMA in 7/8 patients with MDS 
and with karyotype without numerical and/or structural chromosomal changes. Legend: A dotted orange line 
was added to indicate the alignment of chromosomes by centromeres.
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to show variability in its clinical course and response to  treatment1,3,31,32. In this scenario, the identification of 
genomic variants associated with primary MDS could prove widely useful, offering additional information for 
the biological understanding and prognostic classification of this  disease13,15,33,34.
The imbalances, characterized by gains and losses in the genome, represented 31.7% (13/41) of the genomic 
variations identified. Therefore, gene copy gains and losses may result in an increase or decrease/absence of any 
functional transcript. In this context, alterations in gene dosages play a determining role in the quantity of the 
expressed product and, consequently, down-regulate important molecular pathways of hematopoietic progenitor 
cells (HPCs), which are associated with the etiological processes of  MDS35,36.
Expression analysis via a public database indicated that 30.8% (28/91) of the genes in this study located in 
regions with CNVs and LCSHs are up-regulated or down-regulated in the mesenchymal stromal cells of bone 
marrow tissue in patients with MDS, when compared with those of controls. Additionally, alterations in gene 
expression may be related to the inactivation of suppressor genes or the activation of  oncogenes26. These altered 
molecular biological mechanisms may interfere with cell survival and correlate with the expansion of cells with 
ineffective hematopoietic functions, which may contribute to the possibility of the evolution and malignization 
of clinical MDS.
Table 1.  Clinical features, cytogenetic and cytogenomic results, and risk estimates (according to the 
International Prognostic Scoring System—Revised) of a cohort of patients with myelodysplastic syndrome in 
addition to clinical outcomes. F female, M male, NAF no alterations found, LCSH long continuous stretches 
of homozygosity. *ISCN2016: an international system for human cytogenomic chromosome nomenclature. 
**IPSS-R: risk estimates, according to the International Prognostic Scoring System—revised ***No 
cytogenomic rearrangements and no genes were identified using the CMA in the analyzed region. # Estimated 
score according to hemoglobin levels, absolute neutrophil count, platelet count, percentage of blasts in the 
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Of the altered genes, 32.1% (9/28) were down-regulated and 67.9% (19/28) were up-regulated. The main 
functional pathways in which these genes are involved have been identified; in this context, the investigation 
only described the biological processes that may be affected by altered gene expression. This study reports that 
the molecular pathways associated with gene expression control, immune response, and tumor proliferation 
and suppression were the most commonly deregulated. The relationship between RNA polymerase and the eti-
ology of MDS is not well-defined26. One can infer that RNA polymerase dysregulation would alter the normal 
transcription of critical genes, such as tumor suppressor genes (GSTs), because RNA polymerase plays a role in 
modulating DNA transcription.
Identified CNVs harbor 17.9% (5/28) of genes with positive or negative regulation in the mesenchymal 
stromal cells of bone marrow tissue in patients with MDS. In the CNV of genomic loss in 20q, the RALY and 
ADA genes were found to be up-regulated and SLC2A10 and RAB5IF were down-regulated. The ADA and RALY 
genes are associated with immune response pathways and embryonic development, respectively, while the genes 
SLC2A10 and RAB5IF correlate with glucose homeostasis pathways and protein interaction factor, respectively; 
these genes are expressed in the mesenchymal stromal cells of normal bone marrow tissue.
According to reports previously  published37,38, loss of CNVs lead to haploinsufficiency and can inactivate 
GSTs. In addition, the RALY and ADA genes were up-regulated in lost CNVs, suggesting compensation for 
protein products. Therefore, in microdeletion events in the genome, varied molecular mechanisms can occur 
and be associated with the pathophysiology of MDS. Thus, CNVs of genomic loss represent important markers 
with biological significance, providing additional information for understanding the mechanisms and molecular 
pathways related to the etiology and transformation potential of  MDS36.
The MAP2K3 oncogene, located in the CNV with genomic gain in 17p with 0.29 Mb, shows altered expression 
with positive regulation. The protein encoded by this gene is a dual-specificity kinase that belongs to the family of 
map-kinases and is activated by mitogenic and environmental  stress38. Changes in the pathways involving these 
kinases can deregulate molecular processes related to differentiation, cell cycle survival, and control, leading to 
the process of apoptosis in patients with MDS. Imbalances caused by positive gene expression, when compared 
with negative gene expression, may be less unfavorable for cellular biological  pathways37,38. The present study 
Table 2.  Biological functions and expression patterns at diagnosis of (28/91) selected genes in MDS patients 
with karyotypes without numerical or structural changes. *The biological functions of the genes were identified 
via RefSeq (NCBI Reference Sequence Database: http://www.genom e.jp/dbget -bin/www_bget?ds:H0148 
1; Kegg Disease: Myelodysplastic syndrome—Genome Net). **For the analysis of expression through 
public databases of MDS patients, one GEO Dataset from NCBI (https ://www.ncbi.nlm.nih.gov/geo/) was 
downloaded. The transcriptome was based on the study with accession number GSE61853 in which the gene 
expression patterns of mesenchymal bone marrow stromal cells from patients with MDS and normal controls 
were analyzed. The value of logFC was used to define which genes were up-regulated or down-regulated in 
MDS patients with karyotypes without numerical or structural changes.
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confirms this statement, since about 2/3 of the genes are up-regulated and 7/8 patients with no visible changes 
in the karyotype exhibited stable clinical outcomes at the end of the study.
All three gain CNVs involving the 17p11.2 cytoband with different sizes, being 0.29 Mb, 0.13 Mb, and 
0.15 Mb, are significant. Events involving chromosome 17p were considered important due to the proximity of the 
cytoband 17p13.1, which houses the GST TP53. The TP53 protein participates in the regulation and expression of 
several target genes, inducing cell cycle control, apoptosis signaling, cell senescence, and DNA  repair39,40. Muta-
tions in one or both alleles of TP53 can deregulate several molecular pathways involved in about 50% of human 
cancers and 20% of onco-hematologic malignancies, including MDS. Therefore, according to the risk prognosis 
and clinical results, these CNVs with a 17p gain may have a negative effect on hematological evolution and patient 
survival, as evidenced by the patient who died during the course of this study. The other CNVs with genomic 
gain in 2q, 17p, 17q, 21q and Yq, the CNV of genomic loss in 4q, and the LCSHs in 4q, 18q and Xq presented 
in Table 1 were selected as relevant due to the high instability inherent in the genomes of MDS patients, which 
is the basis for the accumulation of mutations in this  disease24. Expression per positive regulation of the ADA 
gene, inserted in a region with genomic loss in 20q, and of the FLT3LG gene in 19q and KLHL5 in 4p, located in 
regions within LCSHs, may be associated with changes in interferon signaling pathways (immune response)41. 
These deregulated pathways in the medullary microenvironment in patients with MDS demonstrate that these 
factors participate in inducing the inflammatory state and immunological disorders, which alters hematopoiesis, 
thereby causing intramedullary apoptosis along with abnormal HPC differentiation and maturation.
LCSHs are abnormalities that represent 68.3% (28/41) of the genomic variations identified in the present 
study. Of the selected genes, 85.7% (78/91) were inserted in regions with LCSHs and associated with biological 
regulatory functions. Additionally, 82.1% (23/28) of up-regulated or down-regulated genes in mesenchymal 
stromal cells in the medullary microenvironment of patients with MDS were located in regions with loss of 
heterozygosity. The pathological potential of LCSHs emerges as a mechanism of clonal alteration in a proportion 
of somatic cells with uniparental disomy (UPD)19,20,42,43. In this context, recurring areas of LCSHs are strongly 
associated with the loss of the wild allele or an entire region, which also leads to the hypothesis of haploinsuf-
ficiency. Thus, these events indicate changes in biological processes that are important to the cells and signal 
a predisposition to hematological  malignancies19,20. The terminal segmental LCSHS identified in 6q, 14q, 18q, 
19q, and 21q presented in Fig. 2 indicates that break-induced replication (BIR) can be a dominant mechanism 
by which a cell duplicates a somatically acquired event, such as a mutation, microdeletion, or epigenetically 
suppressed region, and consequently becomes homozygous for this segment. BIR seems to be a common repair 
mechanism in replication, but only the reduplication of a region that contains a genetic or epigenetic alteration 
gives the cell a growth advantage, allowing for its dominance and clonal selection. Regions with LCSHs involv-
ing 3p, 4p, 10p, 12q, and 16p were identified only in the patient who died. The UCHL1, TMEM33, and OCIAD2 
genes inserted in 4p, the HACD1 gene in 10p, and the POC1B gene in 12q, which encode neural transmission 
functions, transmembrane protein, tumor suppressor, signaling molecule, and centrosome, respectively, were 
down-regulated. Five out of nine selected and down-regulated genes were located in the LCSHs identified in the 
patient who died. Thus, unlike up-regulation, down-regulation events are potentially more damaging to impor-
tant molecular pathways and fundamental cellular functions, as observed in this patient during the hematological 
evolution of the  disease44.
The MX1 gene, located in an LCSH region at 21q, was the most up-regulated, being 2.74-times more expressed 
in bone marrow mesenchymal stromal cells in patients with MDS. This gene encodes a protein that metabolizes 
the guanosine triphosphate (GTP) that participates in the antiviral cellular response. The protein encoded by 
this MX1 gene is induced by the type I and II interferon pathways. In this study, the patients with genomic 
variations involving 21q were classified as having low and very low predicted risk, respectively, with stable 
clinical outcomes. These findings contradict previously  published9 reports that changes involving chromosome 
21 have been observed in more advanced cases of MDS, with a more aggressive evolution and rapid leukemic 
 transformation1,11. On the other hand, the UCHL1 gene inserted in an LCSH region with 4p was the most down-
regulated, being 1.12-times less expressed in the mesenchymal stromal cells of the medullary tissue of the MDS 
patient who died. The gene UCHL1 provides information for the production of the enzyme Ubiquitin Carboxyl-
Terminal Esterase L1, which is involved in the cellular machinery that breaks down unnecessary  substances45. In 
cells, damaged or excess proteins are marked with ubiquitin molecules so that the ubiquitin–proteasome system 
can act as a cellular quality control system.
In patients with MDS, persistent and refractory cytopenias can be induced by cytokines and associated with 
T-cell mediated  myelosuppression46. Alongside this, changes in the medullary microenvironment inhibit the 
growth of HPCs through the high secretion of interferon-gamma (IFN-γ), TNF, and Interleukin-6 (IL-6)14,47. An 
increase in the number of stem cells could offset the phenotypic consequences of the simultaneous repression 
of differentiation genes, creating a pre-leukemic hematopoiesis with little or no morphological  abnormalities48. 
As such, the association between dysplastic cell characteristics and the increase in total genomic changes is an 
observation that suggests a significant parallel trend. Also, the more morphological dysplasia a marrow tissue 
sample presents, the more extensive the underlying genomic changes can  be48. Both events, CNVs and LCSHs, 
contributed significantly to the correlation between the identified genomic variations and the clinical and labora-
tory phenotypes of patients with MDS in this study, highlighting the usefulness of matrix platforms containing 
markers for SNPs.
In only 12.5% (1/8) of the patients, the CMA did not reveal genomic variations. It is important to note that 
this result without changes does not imply that there could not be some kind of deleterious mutation in the 
genes associated with the molecular pathways associated with the MDS phenotypes. Thus, it was not possible 
to suggest a genetic cause for this disease, since the CMA resolution was not comprehensive enough to identify 
changes in the genome. This study highlights that balanced translocations are not detectable by CMA, which is a 
disadvantage of this cytogenomic analysis  technique49,50. The possibility of testing other more sensitive or specific 
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genomic technologies, such as Next Generation Exome Sequencing (NGS), may be a differential approach to 
identify point mutations that may be associated with MDS, in which the etiology is multifactorial and extremely 
 heterogeneous51.
The limitation of this study was the small size of the sample group. This limitation is typical of studies involv-
ing patients with primary MDS, which have reduced casuistry due to the low incidence of the disease in the 
population. The present findings from CNVs and LCSHs can contribute to subsequent studies of the adequate 
characterization of the MDS phenotype and bring additional information to improve the quality of prognostic 
and personalized stratification for the patient, in addition to the possibility of identifying potentially more effec-
tive therapeutic treatments in the near  future13,16. The interpretation and association of CNVs that result in pri-
mary MDS is still challenging, mainly due to the unclear effects of variations in the genome that can be influenced 
by incomplete penetrance, variable expressiveness, and  epistasis40,52,53. In this context, further investigations are 
needed in larger cohorts, including patients with greater heterogeneity of clinical outcomes and prognostic risks.
Conclusion
This study identified and reported CNVs and LCSHs that may be associated with primary MDS in the group of 
participants. Ninety-one genes involved in important molecular pathways of metabolism and cell viability were 
selected. From the analysis of the cytogenomic findings, when compared to information from public genomic 
databases, CNVs and LCSHs were related to bone marrow failure, which was characterized by the expansion 
of cells with ineffective hematopoietic functions. CMA is a robust and efficient cytogenomic technique for 
expanding the resolution of the genomic analysis of the medullary cells of primary MDS patients, allowing the 
identification of unusual and clinically significant genomic variations in patients without visible changes in the 
karyotype. Finally, 30.8% (28/91) of the selected genes showed altered expression and 2/3 of these genes showed 
positive regulation when compared to public data on gene expression in mesenchymal stromal cells of bone 
marrow tissue in primary MDS. Changes in gene expression may be related to the etiology and progression of 
primary MDS, with a resulting effect on the relative risk and clinical outcome of this onco-hematological disease.
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